Everolimus (rad001)    (DrugBank: Everolimus)

3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
34神経線維腫症2
89リンパ脈管筋腫症2
158結節性硬化症6

34. 神経線維腫症 [臨床試験数:120,薬物数:182(DrugBank:72),標的遺伝子数:84,標的パスウェイ数:194
Searched query = "Neurofibromatosis", "NF1", "von Recklinghausen disease", "NF2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 120 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01365468
(ClinicalTrials.gov)
April 201227/5/2011Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1)Plexiform Neurofibroma Associated With Neurofibromatosis Type 1Drug: Everolimus (RAD001)Novartis PharmaceuticalsNULLTerminated6 YearsN/AAll9Phase 2Israel
2NCT01419639
(ClinicalTrials.gov)
October 201117/8/2011Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2Neurofibromatosis Type IIDrug: Everolimus (RAD001) , Afinitor®New York University School of MedicineNovartis Pharmaceuticals;The Children's Tumor FoundationCompleted3 YearsN/AAll10Phase 2United States

89. リンパ脈管筋腫症 [臨床試験数:38,薬物数:42(DrugBank:19),標的遺伝子数:26,標的パスウェイ数:134
Searched query = "Lymphangioleiomyomatosis", "LAM"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 38 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00790400
(ClinicalTrials.gov)
April 200910/11/2008Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)Tuberous Sclerosis Complex (TSC);Lymphangioleiomyomatosis (LAM)Drug: Everolimus (RAD001);Drug: Everolimus PlaceboNovartis PharmaceuticalsNULLCompleted18 YearsN/AAll118Phase 3United States;Canada;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom
2NCT00792766
(ClinicalTrials.gov)
December 200817/11/2008Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Complex and Sporadic LymphangioleiomyomatosisTuberous Sclerosis;AngiolipomaDrug: everolimus (RAD001)Children's Hospital Medical Center, CincinnatiNovartisCompleted18 Years65 YearsBoth20Phase 1;Phase 2United States

158. 結節性硬化症 [臨床試験数:100,薬物数:62(DrugBank:16),標的遺伝子数:35,標的パスウェイ数:115
Searched query = "Tuberous sclerosis", "Tuberous sclerosis complex"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 100 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01954693
(ClinicalTrials.gov)
June 20125/9/2013A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous SclerosisTRON: A Randomised, Double Blind, Placebo-controlled Study of RAD001 (Everolimus) in the Treatment of Neurocognitive Problems in Tuberous SclerosisTuberous SclerosisDrug: Placebo;Drug: Everolimus (RAD001)Cardiff UniversityNovartisUnknown status16 Years60 YearsAll48Phase 2United Kingdom
2NCT01070316
(ClinicalTrials.gov)
January 201015/2/2010Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis ComplexEpilepsy;Tuberous Sclerosis ComplexDrug: EverolimusChildren's Hospital Medical Center, CincinnatiNovartisCompleted2 YearsN/AAll20Phase 1;Phase 2United States
3NCT00789828
(ClinicalTrials.gov)
August 200912/11/2008Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)A Randomized, Double-blind, Placebo-controlled Study of Everolimus in the Treatment of Patients With Subependymal Giant Cell Astrocytomas (SEGA) Associated With Tuberous Sclerosis Complex (TSC)Tuberous Sclerosis;Subependymal Giant Cell AstrocytomaDrug: Everolimus;Drug: PlaceboNovartis PharmaceuticalsNULLCompletedN/AN/AAll117Phase 3United States;Australia;Belgium;Canada;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom
4NCT00790400
(ClinicalTrials.gov)
April 200910/11/2008Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)Tuberous Sclerosis Complex (TSC);Lymphangioleiomyomatosis (LAM)Drug: Everolimus (RAD001);Drug: Everolimus PlaceboNovartis PharmaceuticalsNULLCompleted18 YearsN/AAll118Phase 3United States;Canada;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom
5NCT00792766
(ClinicalTrials.gov)
December 200817/11/2008Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Complex and Sporadic LymphangioleiomyomatosisTuberous Sclerosis;AngiolipomaDrug: everolimus (RAD001)Children's Hospital Medical Center, CincinnatiNovartisCompleted18 Years65 YearsBoth20Phase 1;Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00411619
(ClinicalTrials.gov)
January 200712/12/2006Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis ComplexEverolimus (RAD001)Therapy of Giant Cell Astrocytomas in Patients With Tuberous Sclerosis ComplexTuberous Sclerosis;Subependymal Giant Cell AstrocytomaDrug: EverolimusChildren's Hospital Medical Center, CincinnatiNovartisCompleted3 YearsN/AAll28Phase 1;Phase 2United States